The global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics is estimated at US$30.4 Billion in 2023 and is projected to reach US$54 Billion by 2030, growing at a CAGR of 8.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market]( "Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market")
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Targeted Therapy segment, which is expected to reach US$31.3 Billion by 2030 with a CAGR of a 9.6%. The Immunotherapy segment is also set to grow at 7.5% CAGR over the next 7 years.
- Regional Analysis: Gain insights into the U.S. market, estimated at $7.9 Billion in 2023, and China, forecasted to grow at an impressive 12.9% CAGR to reach $14.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 34 Featured):
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- GlaxoSmithKline plc
- Novartis
- Pfizer Inc.
- Roche Holding AG
- Sun Pharmaceutical Industries Ltd.
MarketGlass Platform
Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Global Economic Update
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 3: World Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 4: World 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 10: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 15: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 16: World 16-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 18: World Historic Review for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 19: World 16-Year Perspective for Squamous Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 21: World Historic Review for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 22: World 16-Year Perspective for Large Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
UNITED STATES
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 24: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 25: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 27: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 28: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 30: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 31: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 33: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 34: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
JAPAN
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 35: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 36: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 37: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 39: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 40: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
CHINA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 41: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 42: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 43: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 45: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 46: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
EUROPE
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 47: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 48: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 49: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 51: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 52: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 54: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 55: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
FRANCE
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 56: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 57: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 58: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 60: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 61: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
GERMANY
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 63: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 64: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 66: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 67: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 69: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 70: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 72: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 73: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 75: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 76: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 78: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 79: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
SPAIN
- Table 80: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 81: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 82: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 83: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 84: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 85: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
RUSSIA
- Table 86: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 87: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 88: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 89: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 90: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 91: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 97: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
AUSTRALIA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
LATIN AMERICA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
MIDDLE EAST
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
AFRICA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- GlaxoSmithKline plc
- Novartis
- Pfizer Inc.
- Roche Holding AG
- Sun Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 89 |
| Published | November 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 30.4 Billion |
| Forecasted Market Value ( USD | $ 54 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
